Quidel Stock News

Quidel Corp''s (NASDAQ: QDEL ) fourth-quarter revenues fell 21.3% Y/Y to $636.87 million , beating the consensus of $567.17 million. The decline was driven mainly by a $249 million revenue decline of the Sofia 2 Flu + SARS antigen FIA. Also impacting revenue was a shift in … Full story available on Benzinga.com

Shares of Quidel (QDEL) jumped 5% in after-hours trading after reporting Q4 2021 results that beat on both the top and bottom lines.

Quidel press release (QDEL): Q4 Non-GAAP EPS of $7.29 beats by $1.97.Revenue of $636.87M (-21.3% Y/Y) beats by $119.49M.Shares +7%.“Moving beyond the fourth quarter, demand for…

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Highlights Signed definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc ("Ortho"), funded through a combination of cash and newly issued shares in the combined company. Total revenue was $636.

Quidel's (QDEL) CEO Doug Bryant on Q4 2021 Results - Earnings Call Transcript

Quidel (QDEL) delivered earnings and revenue surprises of 49.08% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Related Stocks: EBAY , QDEL , BTRS , SKIN , CRTO , CERS , PING , GES , AMWL , SI , RDW , OPAD , FTDR , PLNT , BBD , ALLT , ZNGA , AEVA ,

Las Vegas, USA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Molecular Diagnostics Market is Expected to Grow at a Substantial CAGR of 9.21% and is Contemplated to Reach USD 16.12 Billion by 2026, Estimates DelveInsight Molecular Diagnostics Market is contemplated to witness huge demand in the upcoming years due to rising infectious diseases and their diagnosis, the presence of global as well as regional manufacturers active in developing the Molecular Diagnostic products such as Qiagen, Roche, Molbio Diagnostics Pvt. Ltd., among others. Also, improving healthcare infrastructure, government initiatives in raising awareness regarding molecular diagnosis will contribute to the Molecular Diagnostics market growth in these regions. DelveInsight''s Molecular Diagnostics Market Insights and Forecast report provides the current and forecast Molecular Diagnostics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Molecular Diagnostics Market.

Quidel's (QDEL) fourth-quarter results are likely to reflect continued strength across its SARS-related products.

Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quidel (QDEL) closed at $95.02 in the latest trading session, marking a -1.43% move from the prior day.

Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fou